[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612400":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"EUS-PPG alteration in esophageal varices after ligation",null,[12],"Procedure: Ligation for esophageal varices",{"label":14,"type":15,"description":10,"interventionNames":16},"EUS-PPG alteration in esophageal varices after sclerotherapy","EXPERIMENTAL",[17],"Procedure: Sclerotherapy for esophageal varices",[19,23],{"type":20,"name":21,"description":14,"armGroupLabels":22,"otherNames":10},"PROCEDURE","Sclerotherapy for esophageal varices",[14],{"type":20,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Ligation for esophageal varices","EUS-PPG alteration in esophageal varices after Ligation",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Meng Xue","CONTACT","+86 0571 87783544","xuemeng@zju.edu.cn",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"The Second Affiliated Hospital of Zhejiang University School of Medicine","RECRUITING","Hangzhou","China","CN",{"type":41,"coordinates":42},"Point",[43,44],120.16142,30.29365,{"lat":44,"lon":43},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612400","eus-ppg-alteration-after-ligation-and-sclerotherapy-in-esophageal-varices-100612400",false,"NCT07253090","EUS-PPG Alteration After Ligation and Sclerotherapy in Esophageal Varices","The Comparative Study on the Alteration of Endoscopic Ultrasound Guided Portal Pressure Gradient in Esophageal Varices After Ligation and Sclerotherapy","Inclusion Criteria:\n\nCirrhotic patients admitted for primary\u002Fsecondary prevention due to esophageal and gastric varices, and willing to sign the informed consent form.\n\nExclusion Criteria:\n\n1. Refusing to sign the informed consent form;\n2. Age \\\u003C 18 years, or ≥ 81 years;\n3. Coagulopathy (INR \\> 1.5);\n4. Markedly decreased platelets (\\\u003C20,000\u002FμL);\n5. Propranolol\u002Fcarvedilol was used 24h before admission.","ALL","18 Years","80 Years",{"count":59,"type":60},70,"ESTIMATED","INTERVENTIONAL",[63],"NA","Acute variceal bleeding due to cirrhotic portal hypertension is a life-threatening emergency in gastroenterology. Current preventive strategies include non-selective β-blockers (e.g., carvedilol\u002Fpropranolol), endoscopic therapy (sclerotherapy or band ligation), and transjugular intrahepatic portosystemic shunt (TIPS). While pharmacological and TIPS interventions directly reduce portal pressure, the impact of endoscopic therapies on portal hemodynamics remains controversial. The hepatic venous pressure gradient (HVPG), measured via transjugular catheterization as the difference between wedged and free hepatic venous pressures, is the gold standard for assessing portal pressure. Clinically significant portal hypertension (CSPH) is defined as HVPG ≥10 mmHg, with values \\>12 mmHg predicting variceal formation and bleeding risk.\n\nTraditional views suggest that non-selective β-blockers and transjugular intrahepatic portosystemic shunt (TIPS) can reduce portal vein pressure. Does endoscopic intervention affect portal vein pressure? Previous studies have explored changes in HVPG in the acute phase after esophageal variceal sclerotherapy and ligation therapy, with inconsistent results. In the study by Toyonaga et al., HVPG was rechecked 2 weeks after sclerotherapy, and the average decreased from 17.9 mmHg to 17.6 mmHg (J Hepatol. 1994 Oct;21(4):515-20). In the study by Gonzalo Bada et al., HVPG values increased from 16.5 mmHg to 19.5 mmHg on average 24 hours after ligation therapy (Rev Esp Enferm Dig. 2020 Jun;112(6):456-461). However, in a prospective randomized controlled study conducted by Avgerinos et al., which compared changes in HVPG within 5 days after ligation and sclerotherapy, and found that HVPG significantly increased after sclerotherapy, while there was no significant change in HVPG after ligation (Hepatology. 2004 Jun;39(6):1623-30).\n\nThe investigators speculate that the inconsistent results mentioned above may be related to the limitations of HVPG, which inaccurately reflects pre-sinusoidal\u002Fextrahepatic portal hypertension and is influenced by technical factors (e.g., catheter position, sedation). Emerging evidence suggests endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement may overcome these limitations. Recent studies demonstrate strong correlations between EUS-PPG and HVPG, as well as associations with variceal severity and Child-Pugh class. However, data on chronic portal pressure changes (≥3 months) post-endoscopic therapy are lacking.\n\nThis prospective study aims to evaluate chronic changes in EUS-PPG 3-6 months after endoscopic variceal ligation (EVL) or sclerotherapy in cirrhotic patients receiving primary\u002Fsecondary prophylaxis.",[66],"Esophagogastric Varices","2025-11-24",{"date":69,"type":70},"2025-11-28","ACTUAL",{"date":72,"type":70},"2025-08-18",{"date":74,"type":60},"2026-12-31",{"name":5,"class":6},1]